K
Kira Biotech
Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders
About Kira Biotech
Kirabiotech is a startup operating in the biotechnology sector, leveraging the extensive experience of its management team in pharmaceuticals and business development. The company is led by Michael Grissinger, a seasoned professional with a 22-year career at Johnson & Johnson, where he held various leadership roles in Mergers and Acquisitions, Corporate Development for Pharmaceuticals, and Pharmaceutical Business Development and Licensing. He has a proven track record of leading transactions and teams across diverse deal-types, geographies, and therapeutic disease areas.
The CEO, Dan Baker, is a medical professional with a background in Biology and a medical degree from the University of Pennsylvania. He has a rich experience in clinical development of immunology drugs and has authored multiple publications in the field. His previous roles include Vice President Immunology R&D at Janssen, where he was responsible for clinical development plans for rheumatology products and the overall strategy on portfolio in rheumatology/immunology.
The company's business model is not explicitly stated, but given the backgrounds of the management team, it is likely that Kirabiotech is involved in the development and licensing of biotech and pharmaceutical products. The company's clients would likely be other pharmaceutical companies, healthcare providers, and possibly research institutions. The company would generate revenue through the licensing of its products, partnerships with other companies, and possibly through the sale of its products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Brisbane, Australia
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 59.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B, B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2019 | $20M | $80M | IP Group | — |
| SPINOUT✓Other financing | Jan 2019 | $0 | — | University of Sydney | — |
Growth signals
Latest recorded traffic for Kira Biotech is 920 monthly website visits, down 42.5% over the last three months. Kira Biotech's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kira Biotech in the Brisbane ecosystem
The Kira Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
IP Group
Other known investors3 additional known investors
University of Sydney
IP Group Australia
One Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kira Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kira Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









